Why Attend the 4th Cell Therapy for Autoimmune Disease Summit?
As autoimmune cell therapy transitions from breakthrough case studies to broad clinical validation, 2026 represents a pivotal year for the industry. At the 4th Cell Therapy for Autoimmune Disease Summit, join the only dedicated forum that brings together developers of CAR-T, NK, Treg, MSC, and in vivo cell therapies to discuss the latest clinical readouts, translational strategies, and commercialization considerations shaping the future of immune reset therapies.
With two focused content tracks on Preclinical Development & Translation and Clinical Development, dedicated networking opportunities, investor and pharma perspectives, and discussions spanning lupus, multiple sclerosis, type 1 diabetes, stiff person syndrome, and beyond, this summit provides a comprehensive view of where the field is headed next.
![CB-CDx-0107-min-scaled11[1]](https://cell-therapy-autoimmune-disease.com/wp-content/uploads/sites/286/2026/02/CB-CDx-0107-min-scaled111.jpg "CB-CDx-0107-min-scaled11[1]")
What to Expect in 2026?
Analyze Transformative Clinical Readouts
Benchmark the latest CAR-T, NK, and Treg therapy data alongside leaders from Moderna and understand what these results mean for the future treatment paradigm.
Evaluate Next-Generation Autoimmune Cell Therapy Platforms
Discover how Kite Pharma is advancing novel engineering strategies designed to improve efficacy, durability, and safety across autoimmune indications.
Explore Scalable In Vivo Approaches
Hear from CPTx as the field looks beyond traditional manufacturing models and towards in vivo engineered cell therapies capable of serving larger patient populations.
Learn Global Clinical Development Strategies
Gain insights from Overland Therapeutics on accelerating development through innovative trial designs, regional partnerships, and emerging autoimmune opportunities.
Prepare for Commercial Adoption
Understand the challenges of bringing autoimmune cell therapies to broader patient populations with perspectives from Artiva Biotherapeutics on access, scalability, and long-term adoption.
Connect with the Next Wave of Industry Leaders
Network directly with pioneers, including PolTREG and other innovators, driving the transition from proof-of-concept studies to potentially curative therapies.
Divide & Conquer Across the Two Tracks
To maximize your team's impact, the 2026 agenda features two dedicated tracks designed to support both preclinical and clinical development priorities. With representation from C-suite leadership, scientific teams, and business development professionals, attendees will gain practical insights that can be applied across their programs.
Take advantage of our group discounts to enable colleagues from different functions to divide coverage across the agenda and bring back a broader range of learnings to your organization. Get in touch with the team to learn more.
Preclinical & Translational Track
Designed for teams advancing the next generation of autoimmune cell therapies, this track enables deeper discussions on the scientific and translational challenges that shape clinical success.
By bringing together discovery, translational, and platform development leaders from Kite Pharma, CPTx, Cabaletta Bio, and Sail Biomedicines, attendees can benchmark emerging approaches earlier in development, validate strategic decisions, and gain practical insights that are often difficult to access in clinically focused forums.
Clinical Track
Built for developers navigating the realities of clinical execution, this track provides a dedicated forum to learn from peers generating data across autoimmune indications.
Hear firsthand experiences from leaders at Artiva Biotherapeutics, Mesoblast, PolTREG, Moderna, and Medical University of South Carolina, gaining actionable insights on translating promising science into meaningful patient outcomes, overcoming operational and regulatory challenges, and preparing programs for long-term clinical and commercial success.
Access Your Copy of the Agenda to Discover:
- 25+ Industry & Academic Leaders sharing the data and lessons learned, shaping the future of autoimmune cell therapy
- 2 Dedicated Tracks to provide every member of your organization a personalized experience and return with actionable insights
- 8+ Hours of Structured Networking to connect with global autoimmune leaders
- An Exclusive Investor & Pharma Insights Panel outlining the qualities they look for when funding the next generation of autoimmune cures
- Clinical, Translational & Commercialization Insights that are essential for the continued progress and scaling of cell therapies
Who Can You Connect With?
![CB-CDx-0690-min-scaled11[1]](https://cell-therapy-autoimmune-disease.com/wp-content/uploads/sites/286/2024/06/CB-CDx-0690-min-scaled111.jpg "CB-CDx-0690-min-scaled11[1]")
Explore the Agenda
Discover the latest clinical breakthroughs, translational advances, and commercialization strategies shaping autoimmune cell therapy.
Partner With Us
Connect with the industry's leading autoimmune cell therapy developers as they navigate the next phase of clinical and commercial growth.
Join Cell Therapy Leaders
Attend a highly focused meeting designed specifically for autoimmune disease, enabling more relevant discussions and meaningful connections with peers facing similar challenges.